Teijin is revising its medium-term management plan for publication in 2026 and is moving from a materials-led model to a customer-led one. 北紡's surge has brought into focus the current situation, in which business risks centered on aramid, carbon fiber and pharmaceuticals intersect with tailwinds from defense and EV demand.
Teijin has positioned its medium-term management plan for publication in May 2026 and is pursuing a shift from a materials-centered business to one focused on solving customer problems. The company has explained that it aims to develop a solutions-based model combining materials and services.
The earnings summary indicates that impairment losses will arise in aramid, carbon fiber and pharmaceuticals in the fiscal year ending March 2026, with a net loss of ¥88 billion forecast. The impact of oversupply and price competition in its core materials has also been highlighted, indicating that the outlook for earnings recovery is difficult to assess based on thematic appeal alone.
北紡 (3409), a related company of 北紘紬, recorded a sharp surge accompanied by a substantial increase in trading volume in late October, while Teijin, said to be the ordering party, is quietly advancing its business restructuring.
Teijin's operations extend beyond aramid, carbon fiber, resins and pharmaceuticals to the home healthcare sector. The company has explained that it is preparing to shift from the conventional approach of "selling materials" toward "solving customers' problems."